Compare Medpace Holdings Inc (MEDP) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Medpace Holdings Inc trades at $615.95 (market cap $16.82B), while YieldMax NVDA Option Income Strategy ETF trades at $12.59 (market cap $1.45B). The key difference: Medpace Holdings Inc is far larger — about 11.6× YieldMax NVDA Option Income Strategy ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| MEDP | NVDY | |
|---|---|---|
Market Cap | $16.82B | $1.45B |
Volume | 223,093 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $630.19 | $17.21 |
52-Week Low | $393.42 | $11.58 |
Typical Hold Time | 14 Days | 43 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
NVDY trades at $12.565, down 3.42% today amid bearish technical signals. The ETF shows consistent weekly dividend distributions but faces structural limitations on upside participation. Recent analyst coverage highlights declining volatility in underlying NVDA shares, reducing option income potential while NAV erosion remains a concern.
Outlook remains cautious as the fund's high distribution yield comes at the cost of long-term capital appreciation. Key risks include capped upside participation and dependency on NVDA volatility. Investors seeking pure NVDA exposure may find direct ownership more attractive for growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
